| ¿µ¹® | thyroid carcinoma | ÇÑ±Û | °©»ó»ù¾ÏÁ¾ |
|---|---|---|---|
| ¼³¸í | °©»ó»ù¿¡ »ý±ä »óÇǼ¼Æ÷·Î ÀÌ·ç¾îÁø ¾Ç¼ºÁ¾¾ç¹°. º´¸®Á¶Á÷ÇÐÀûÀÎ ÇüÅ¿¡ µû¶ó À¯µÎ»ó, ¼ÒÆ÷»ó, ¿ªÇü¾ÏÁ¾ ¹× ¼öÁú¾ÏÁ¾, ¸²ÇÁÁ¾ µîÀ¸·Î ³ª´ ¼ö ÀÖ´Ù. ´Ù¾çÇÑ ¿øÀÎÀÌ ÀÖÀ¸³ª, ÀϺο¡¼´Â ¹æ»ç¼±Æø·Î¿¡ ÀÇÇØ ¹ß»ýÇÑ´Ù. Ä¡·á´Â ¼ö¼ú, ¹æ»ç¼º ¿Á¼Ò, T4 ¾ïÁ¦¿ä¹ý µîÀÌ »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | bronchogenic carcinoma | ÇÑ±Û | ±â°üÁö¿ø¼º ¾ÏÁ¾ |
|---|---|---|---|
| ¼³¸í | ÆóÀÇ ±â°üÁö ¼¼Æ÷¿¡¼ ±â¿øÇÏ´Â Á¾¾ç. Æó¾ÏÀÇ Á¾·ù¿¡¼ °¡Àå ÈçÇÑ ÇüÅÂ(90%ÀÌ»ó)ÀÌ´Ù. Çö¹Ì°æÀû ¼Ò°ß¿¡ µû¶ó »ù¾ÏÁ¾, Å«¼¼Æ÷¾ÏÁ¾, ¼Ò¼¼Æ÷(ÀÛÀº¼¼Æ÷) ¾ÏÁ¾ÀÇ 4°¡Áö·Î ³ª´«´Ù. ÀÌÁß¿¡¼ ÆíÆò¼¼Æ÷¾ÏÁ¾ÀÌ °¡Àå ÈçÇÑ ÇüÅÂÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ºñ¼Ò¼¼Æ÷Æó¾Ï(non-small cell lung cancer)¿Í ¼Ò¼¼Æ÷Æó¾Ï(small cell lung cancer)·Î ±¸ºÐÀ» Çϴµ¥, ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ °æ¿ì Á¾¾ç¼¼Æ÷ÀÇ ¼ºÀåÀÌ ´À¸®°í ¼ö¼úÀû Á¦°Å°¡ Ä¡·áÀÇ ±âº»ÀÌ µÇ°í ¿¹Èĵµ ÁÁÀº ¹Ý¸é, ¼Ò¼¼Æ÷Æó¾ÏÀÇ °æ¿ì¿¡´Â ¾Ï¼¼Æ÷ÀÇ ¼ºÀåÀÌ ¸Å¿ì ºü¸£°í Ä¡·áµµ ¹æ»ç¼±Ä¡·á¸¦ ±âº»À¸·Î ÇÏ¸ç ¿¹Èĵµ ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡ ºñÇØ¼ ÁÁÁö°¡ ¸øÇÏ´Ù. |
||
| ¿µ¹® | embryonal carcinoma | ÇÑ±Û | ¹è¾Æ¾ÏÁ¾ |
|---|---|---|---|
| ¼³¸í | »ý½Ä¼¼Æ÷¿¡¼ »ý±â´Â ¾ÏÁ¾ÀÇ Çϳª·Î ´ëºÎºÐ °íȯ¿¡¼ ¹ß»ýÇÑ´Ù. µå¹°°Ô´Â Á¾°Ýµ¿¿¡¼µµ ¹ß»ýÇÑ´Ù. 40~50´ëÀÇ ³²¼º¿¡°Ô ¸¹À¸³ª, À̺¸´Ù ³·Àº ¿¬·ÉÃþ¿¡¼µµ ³ªÅ¸³´Ù. À°¾ÈÀûÀ¸·Î´Â ȸ¹é»öÀÇ ºÐ¿±À» º¸ÀÌ´Â µ¢¾î¸®¸¦ Çü¼ºÇϸç, °íȯ ¾Ç¼º Á¾¾ç Áß ¿¹Èİ¡ ÁÁÀº ÆíÀÌ´Ù. Ä¡·áÀÇ ¿øÄ¢Àº °¡±ÞÀû ½Å¼ÓÇÏ°Ô ¿ø¹ß¼Ò¸¦ ÀýÁ¦ÇÏ°í ¿¹»óµÇ´Â ÀüÀ̺´ÅÍ¿¡ ´ëÇÏ¿© ¹æ»ç¼± Á¶»ç¿ä¹ýÀ» ÇàÇØ¾ß ÇÑ´Ù. Å»ý¾ÏÁ¾ ¹æ»ç¼±¿ä¹ý¿¡ ´ëÇÏ¿© ¸Å¿ì °¨¼ö¼ºÀÌ ³ô±â ¶§¹®¿¡ º´±â°¡ ÃʱâÀ̸é 90% ÀÌ»óÀÇ Ä¡·á°¡ ±â´ëµÈ´Ù. ±×¸®°í ÈÇпä¹ýÁ¦¿¡ ÀÇÇØ ±× Ä¡·á¼º°ú°¡ »ó½ÂÇϰí ÀÖ´Ù. |
||
| ¿µ¹® | carcinoma in situ | ÇÑ±Û | »óÇdz»¾ÏÁ¾ |
|---|---|---|---|
| ¼³¸í | ½ÅüÀÇ ³»ºÎ³ª ¿ÜºÎ¸¦ ½×°í ÀÖ´Â Á¶Á÷À» »óÇǶó°í ÇÑ´Ù. ÀÌ »óÇÇÀÇ ¾Æ·¡¿¡´Â ´ë°³ »óÇǸ¦ ÁöÁöÇϰí ÀÖ´Â Á¶Á÷ÀÇ À§¿¡ Á¸ÀçÇÑ´Ù. ±×¸®°í ÀÌ ÁöÁöÁ¶Á÷°ú »óÇÇ »çÀÌ¿¡´Â ±âÀú¸·À̶ó´Â ¸·ÀÌ ÀÖ¾î¼ »óÇÇ¿Í ÁöÁöÁ¶Á÷À» ±¸ºÐÇØ ÁØ´Ù. ¾ÏÁ¾(carcinoma)¶õ »óÇÇÀÇ ¼¼Æ÷°¡ ¾Ç¼º º¯È¸¦ ÇÏ¿© »ý±â´Â ¾ÏÀ» ¸»ÇÑ´Ù. Á¦ÀÚ¸®¾ÏÁ¾À̶õ ¾ÏÁ¾ÀÇ ÇÑ Á¾·ù·Î ¾ÏÁ¾ÀÌ ±âÀú¸·À» ¹þ¾î³ªÁö ¸øÇÏ°í »óÇdz» Áï, Á¦ÀÚ¸®¿¡ ¸Ó¹°·¯ ÀÖ´Â °æ¿ì¸¦ ¸»ÇÑ´Ù. |
||
| ¿µ¹® | carcinoma | ÇÑ±Û | ¾ÏÁ¾ |
|---|---|---|---|
| ¼³¸í | ¾ÏÁ¾À̶õ »óÇǼ¼Æ÷(-½ÅüÀÇ ³»ºÎ³ª ¿ÜºÎ¸¦ ½×°í ÀÖ´Â Á¶Á÷À» »óÇǶó°í Çϰí, »óÇǸ¦ ÀÌ·ç°í ÀÖ´Â ¼¼Æ÷¸¦ »óÇǼ¼Æ÷¶ó°í ÇÑ´Ù)ÀÇ °úµµÇÑ Áõ½Ä¿¡ÀÇÇÑ ¾Ç¼ºÁ¾¾çÀ» À̸£´Â ¸»ÀÌ´Ù. |
||
| ACC | accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst... |
|---|---|
| EAC | Ehrlich ascites carcinoma; electroacupuncture; epithelioma adenoides cysticum; erythema annulare cen... |
| AFP | Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
| EAT | Eating Attitudes Test; Ehrlich ascites tumor; electro-aerosol therapy; epidermolysis acuta toxica; e... |
| EATC | Ehrlich ascites tumor cell |
| EAC | Ehrlich Ascites Carcinoma |
|---|---|
| EAT | Ehrlich Ascites Tumor |
| EA | Ehrlich Ascites |
| EATC | Ehrlich Ascites tumour cells |
| TCC | Transitional Cell Carcinoma |
| carcinoma, ehrlich tumour | A transplantable, poorly differentiated malignant tumour which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms. (12 Dec 1998) |
|---|---|
| tumor | 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant. 2. Swelling, one of the cardinal signs of inflammations, morbid enlargement. Origin: L. Tumere = to swell (12 May 1997) |
| tumor marker | <investigation, oncology> A substance in the body that usually indicates the presence of cancer. These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples. Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH). They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids. (18 Jul 2002) |
| tumor necrosis factor | <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin. Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine. Synonym: cachectin. Acronym: TNF (13 Nov 1997) |
| Paul Ehrlich | <person> A brilliant scientist and student, born in Silesia, Germany, who at the age of 23 published his first scientific paper which was on the discovery of the mast cells - a name coined by him (1887). While a resident in medicine at Charite Hospital in Berlin he utilised the newly discovered aniline dyes to develop some of the basic methods of histology. Among his contributions are: The preparation and staining of blood smears, he demonstrated granules in leukocytes, described the neutrophil, basophil, eosinophil, myelocyte, and mononuclear cells (white blood cells), he demonstrated normoblasts, megaloblasts and microblasts of the erythrocytic (red blood cell) series. In 1887, he differentiated lymphocytic leukaemia from "bone marrow leukaemia" (myeloid) on blood smear, in 1888, he described aplastic anaemia, in 1882 the diazo reaction of typhoid urines, in 1882, less than six weeks after Koch described the Tuberculus bacillus, Ehrlich had described its acid-fastness and devised the fuchsin stain to demonstrate the pink rod on a blue background. Ehrlich fell ill with tuberculosis and went to Egypt for 3 years for rest and cure. Following his return, he entered the field of immunology. at Von Behring's request, he developed means of standardising antitoxin dosage (immunization units). at the age of 42, he became director of the "Royal Institute for Standardisation and Investigation of Antitoxic Sera." Here he devised his famous "side-chain" theory of immunisation. It has since been replaced. Paul Ehrlich reinvestigated Bordet's alexin and heat-stable substance and named them "complement" and "immune body". Ehrlich coined the terms and created a new science of chemotherapy. In 1910 he discovered Salvarsan or 606, a therapeutic antiluetic. For his silver bullet (Salvarsan) in 1908, he received the Nobel Prize. This scientist was greatly concerned over the problem of drug fastness which still remains a problem. He died August 20, 1915. Lived: 1854-1915. (18 Nov 1997) |
| Heinz-Ehrlich body | A round oxyphil body found in the red blood cell in case of haemocytolysis due to a specific blood poison. Synonym: Heinz-Ehrlich body. (05 Mar 2000) |
| Ehrlich | Paul, German bacteriologist, immunologist, and Nobel laureate, 1854-1915. See: Ehrlichia, Ehrlich's anaemia, Ehrlich's inner body, Ehrlich's phenomenon, Ehrlich's postulate, Ehrlich's diazo reagent, Ehrlich's theory, Ehrlich-Turk line. See entries under stain; reaction. (05 Mar 2000) |
| Ehrlich, Paul | <person> A brilliant scientist and student, born in Silesia, Germany, who at the age of 23 published his first scientific paper which was on the discovery of the mast cells - a name coined by him (1887). While a resident in medicine at Charite Hospital in Berlin he utilised the newly discovered aniline dyes to develop some of the basic methods of histology. Among his contributions are: The preparation and staining of blood smears, he demonstrated granules in leukocytes, described the neutrophil, basophil, eosinophil, myelocyte, and mononuclear cells (white blood cells), he demonstrated normoblasts, megaloblasts and microblasts of the erythrocytic (red blood cell) series. In 1887, he differentiated lymphocytic leukaemia from "bone marrow leukaemia" (myeloid) on blood smear, in 1888, he described aplastic anaemia, in 1882 the diazo reaction of typhoid urines, in 1882, less than six weeks after Koch described the Tuberculus bacillus, Ehrlich had described its acid-fastness and devised the fuchsin stain to demonstrate the pink rod on a blue background. Ehrlich fell ill with tuberculosis and went to Egypt for 3 years for rest and cure. Following his return, he entered the field of immunology. at Von Behring's request, he developed means of standardising antitoxin dosage (immunization units). at the age of 42, he became director of the "Royal Institute for Standardisation and Investigation of Antitoxic Sera." Here he devised his famous "side-chain" theory of immunisation. It has since been replaced. Paul Ehrlich reinvestigated Bordet's alexin and heat-stable substance and named them "complement" and "immune body". Ehrlich coined the terms and created a new science of chemotherapy. In 1910 he discovered Salvarsan or 606, a therapeutic antiluetic. For his silver bullet (Salvarsan) in 1908, he received the Nobel Prize. This scientist was greatly concerned over the problem of drug fastness which still remains a problem. He died August 20, 1915. Lived: 1854-1915. (18 Nov 1997) |
| Ehrlich reaction | The reaction of the indole derivatives with aromatic aldehydes; e.g., tryptophan and p-dimethylaminobenzaldehyde in H2SO4 give a red-violet colour useful in assaying proteins for tryptophan content. Synonym: Ehrlich reaction. (05 Mar 2000) |
| Ehrlich's acid haematoxylin stain | <technique> An alum type of haematoxylin stain used as a regressive staining method for nuclei, followed by differentiation to required staining intensity; the solution may be allowed to ripen naturally in sunlight or partially oxidised with sodium iodate. (05 Mar 2000) |
| Ehrlich's anaemia | <haematology> This form of anaemia occurs when the bone marrow ceases sufficient red and white blood cell production. It may be induced by exposures to high levels of toxic chemicals, radiation and certain drugs. It is generally unresponsive to specific therapy, often accompanied by granulocytopenia and thrombocytopenia, in which the bone marrow may not necessarily be hypocellular or hypoplastic but fails to produce adequate numbers of peripheral blood elements. The term actually is all inclusive and most probably encompasses several clinical syndromes. Origin: Gr. Haima = blood (29 Sep 1997) |
| Ehrlich's aniline crystal violet stain | <technique> A stain for Gram-positive bacteria. (05 Mar 2000) |
| Ehrlich's benzaldehyde reaction | A test for urobilinogen in the urine, by dissolving 2 g of dimethyl-p-aminobenzaldehyde in 100 ml of 5% hydrochloric acid and adding this reagent to urine; a red colour in the cold indicates the presence of an excessive amount of urobilinogen. (05 Mar 2000) |
| Ehrlich's diazo reaction | The reaction of diazotised sulfanilic acid with bilirubin to form azobilirubin, which forms the basis of quantitating the amount of bilirubin in biological fluids. See: van den Bergh's test. Synonym: Ehrlich's diazo reaction. (05 Mar 2000) |
| Ehrlich's diazo reagent | Two solutions, one of sodium nitrite, the other of acidified sulfanilic acid, used in bringing about diazotization. Synonym: Ehrlich's diazo reagent. (05 Mar 2000) |
Synonyms : Ascites Tumor, Ehrlich, Ehrlich Tumor Carcinoma, Tumor, Ehrlich Ascites
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|